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Abstract
Background: There is substantial evidence that methylphenidate (MPH; Ritalin), is being used by
healthy university students for non-medical motives such as the improvement of concentration,
alertness, and academic performance. The scope and potential consequences of the non-medical
use of MPH upon healthcare and society bring about many points of view.
Methods: To gain insight into key ethical and social issues on the non-medical use of MPH, we
examined discourses in the print media, bioethics literature, and public health literature.
Results: Our study identified three diverging paradigms with varying perspectives on the nature
of performance enhancement. The beneficial effects of MPH on normal cognition were generally
portrayed enthusiastically in the print media and bioethics discourses but supported by scant
information on associated risks. Overall, we found a variety of perspectives regarding ethical, legal
and social issues related to the non-medical use of MPH for performance enhancement and its
impact upon social practices and institutions. The exception to this was public health discourse
which took a strong stance against the non-medical use of MPH typically viewed as a form of
prescription abuse or misuse. Wide-ranging recommendations for prevention of further non-
medical use of MPH included legislation and increased public education.
Conclusion: Some positive portrayals of the non-medical use of MPH for performance
enhancement in the print media and bioethics discourses could entice further uses. Medicine and
society need to prepare for more prevalent non-medical uses of neuropharmaceuticals by fostering
better informed public debates.
Background
The non-medical use of neuropharmaceuticals is generat-
ing substantial debates in medical and public health cir-
cles [1,2]. A key motive for this non-medical use of
neuropharmaceuticals is the enhancement of cognitive
function in healthy individuals beyond normal human
capacity [3-5]. There is substantial evidence that methyl-
phenidate (MPH; Ritalin), a drug prescribed to manage
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(AD/HD) in children and adults, is being misused by
healthy university students to improve concentration,
alertness, and academic performance [6]. Much of this
evidence has reported non-medical use of MPH in student
populations but discussions of its ethical ramifications
have also extended toward professional environments
[7,8].
Methylphenidate is one of the most commonly used stim-
ulants in the management of AD/HD symptoms [9,10].
This stimulant is associated with a high abuse potential
[11-14] which has contributed to its classification as a
scheduled substance in both the United States and Can-
ada but continues to be used alongside newer slow release
preparations. Academics and stakeholders have debated
its prescription, and overprescription, making this stimu-
lant a familiar name for healthcare providers and the pub-
lic [15,16]. However, the debate on performance
enhancement differs in that MPH is now being used for
purposes unrelated to AD/HD. Furthermore, performance
enhancement is distinct from "off-label" uses by physi-
cians because performance enhancement uses are neither
medically prescribed nor supervised. Recent studies have
reported that this form of performance enhancement is a
reality affecting North American university campuses but
coverage in international print media suggests broader rel-
evance [17-21]. Studies of prevalence rates show a range
from 6.9% [22] to 35.3% [23] for prescription stimulant
misuse in this student population. Closer examination of
the motives behind the non-medical use of prescription
stimulants yields rates from 3.2% up to 11% for the spe-
cific goals of improving concentration, alertness and aca-
demic performance [5]. Consequently, some scholarly
ethical debates on the non-medical use of MPH have sur-
faced notably because: "In contrast to the other neuro-
technologies [...] whose potential use for enhancement is
still hypothetical, pharmacological enhancement has
already begun" [3].
The scope and potential consequences of the non-medical
use of MPH upon healthcare and society are wide-ranging
and bring about many points of view and various dis-
courses. In particular, media discourses can have impor-
tant consequences on the practice of frontier health
interventions and human welfare by shaping ethical
debates and influencing public acceptance of neurotech-
nological innovation [24,25]. Accordingly, many fear that
the public misunderstands the promises of neuroscience
and their limitations [26,27] based on exaggerated or
unbalanced media accounts. Consequently, it is impor-
tant to examine the debate on pharmacological perform-
ance enhancement in the public sphere. This paper
reports the results of a study which aimed to review and
compare print media coverage with existing bioethics and
public health discourses on the non-medical use of MPH
for performance enhancement.
Methods
This research aimed to analyze discourses on the non-
medical use of MPH to enhance cognitive and academic
performances. We examined discourses on the non-medi-
cal use of MPH in the print media (PM), bioethics litera-
ture (B), and public health literature (PH) based on
previous work suggesting significant differences [5].
Sampling
We generated the print media sample for this study using
the Factiva and LexisNexis Academic databases consisting
of full-text news, business, and law resources. We searched
for English language newspaper articles published from
01/01/2000 to 11/14/2006 using guided news search
options [28]. The start date of 2000 was chosen given the
report of non-medical use of MPH in college students in
the early 2000s [29]. Multiple keyword searches were used
to identify articles discussing the non-medical use of MPH
(Table 1). Keywords were searched in headline, lead para-
graph(s) and general news (major papers) in Factiva and
LexisNexis Academic databases. Bioethics and public health
publications were sought using standard databases. All
articles yielded by the searches were carefully examined
for relevance, the key criteria being the discussion of the
non-medical use of MPH. Individual articles were the
sampling units.
Coding
The content of all articles was coded systematically using
the QSR NVivo 7 software (Doncaster, Australia). The
inductively-generated coding guide and grid were inspired
by previous content analyses of print media [28,30,31]
but adapted to our object of research. Adaptation of the
coding guide was pursued through multiple rounds of
piloting and test coding on a sub-sample of print media
articles to ensure validity and robustness [32]. Key codes
were derived through an inductive process in which previ-
ously used coding categories for content analysis [31]
were refined and adjusted to the context of non-medical
use of MPH. This coding guide defined each category and
provided both an explicit (upper limit) and implicit
(lower limit) example of what each code could be applied
to. After the initial coding of the whole sample by one
member of the research team, two other members of the
research team reviewed the content of each category to
ensure reliability of coding by consensus and ensure that
each code was within the limits established by the coding
guide. The final coding structure included four major
areas (Additional file 1): (1) description of the non-med-
ical use of MPH; (2) workings and effects of MPH, includ-
ing positive and negative effects associated with non-
medical use of MPH; (3) description of ethical, social, andPage 2 of 13
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(4) recommendations for the prevention of the non-med-
ical use of MPH. Coding of the ethical, legal and social
content was furthered by determining if the coded state-
ments affirmed, negated, or remained neutral or ambiva-
lent regarding the issue at stake.
Given our goal of also examining different ethical, social
and legal issues surrounding the non-medical use of
MPH, we report the frequency and distribution of various
codes. Data is reported to illustrate the nature of state-
ments found within discourses and contrast discourses on
the non-medical use of MPH.
Results
Portrayal of non-medical uses of MPH in different 
discourses
We first examined how the non-medical use of MPH for
performance enhancement was portrayed in the media in
comparison to scholarly bioethics and public health dis-
courses. We found that a wide array of terms was used in
the print media [18-21,33-38], many of which conferred
a sense of familiarity and efficacy (e.g., "study aid", "study
tool") regarding this form of MPH use (Table 2).
In the media, typical statements described the non-medi-
cal use of MPH for performance enhancement as a life-
style choice or a form of illicit street drug (e.g., "better
living through chemistry") [18,39] while the formal term
of "cognitive enhancement" was found almost exclusively
in bioethics discourse [40]. Public health discourse
described this practice negatively as a form of illicit pre-
scription drug misuse or abuse [41] (Table 3). Headlines
used in different discourses reflected these divergent
Table 1: Generation of sample for analysis of discourses on the non-medical use of methylphenidate.
Discourse Databases Keywords Articles (n)
Print media Lexis-Nexis Academic Factiva "Ritalin"
"methylphenidate"
"smart drugs"







Bioethics literature PubMed (bioethics limit) Expanded Academic 14
Public health literature PubMed Expanded Academic 7
* We found a single article repeated four times (N = 23 articles) but kept the twenty distinct articles for analysis (except for the headline analysis 
since all 23 headlines were distinct).
† Articles originated from the USA (n = 11), UK (n = 6), Australia (n = 2) and Canada (n = 1).
Table 2: Occurrences of lay designations of methylphenidate 
used non-medically for performance enhancement in the print 
media
Lay designation Occurrences
"study aid" [37] 9
"brain steroid" [18] 4
"smart drug(s)" [21] 4
"vitamin R" [37] 4
"poor man's cocaine" [33] 3
"study tool(s)" [18] 2
"wonder drug" [38] 2
"new chemical aid" [18] 1
"smart pill(s)" [35] 1
"cramming drug" [34] 1
"academic steroids" [37] 1
"steroids of academia" [20] 1
"legal speed" [36] 1
"kiddie speed" [19] 1Page 3 of 13
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Table 3: Portrayal of the non-medical use of methylphenidate in print media, bioethics and public health supported by examples of 
article headlines as well as the occurrence of reported risks and benefits indicated in parentheses (n).
Print media
Portrayal “Lifestyle choice”: “better living through chemistry” [39]; “short cut in learning”;  “new kind of drug abuse” [18].
Examples of headlines "Students taking danger drug to help with exams"; " 'Smart pills' are on the rise. But is taking them wise?"; "New campus high: 
Illicit prescription drugs".
Reported risks* Physiological addiction (8); palpitations (7); psychological addiction (6); heart attack (5); unspecified cardiac risks (4); loss of 
appetite (4); hallucinations (4); stroke (2); tremors (2); increase in blood pressure (2); weight loss (2); vomiting (2); dizziness 
(2); seizures (2); withdrawal symptoms (2); require increasing amounts of drug (1); cardiac arrhythmia (1); overdose (1); 
changes in brain cell chemistry (1); fatigue (1); death (1); dry mouth (1).
Reported benefits† Boost concentration (8); increase focus (7); increase energy (3); increase alertness (1); reduce appetite (1); eliminate jitters 
(1); filter out distractions (1); increase motivation (1); accumulate more information in less time (1); increase confidence (1); 
increase organization (1); increase retention of information (1); think more rationally (1); general feeling of well-being (1); 
make you feel smarter (1); make mundane tasks seem fun (1); enhance studying (1); do work faster (1); maintain high 
performance level (1); boost brain activity (1).
Bioethics
Portrayal "Cognitive enhancement": " 'neuroenhancement' (...) This term includes the use of drugs and other interventions to modify 
brain processes with the aim of enhancing memory, mood and attention in people who are not impaired by illness or 
disorder"[40].
Examples of headlines "Neurocognitive enhancement: what can we do and what should we do?" and "Cosmetic neurology: The controversy over 
enhancing movement, mentation, and mood".
Reported risks* Addiction (3); toxicity (1).
Reported benefits† Improve attention (4); improve memory (4); improve performance (2); increase focus (1); improve concentration (1); 
improve planning (1); think faster (1); stabilize mood (1); promote creativity (1).
Public health
Portrayal "Abuse", "misuse", "illicit drug use": "Ritalin (Novartis Pharmaceuticals Corp., East Hanover, NJ) has received the most 
attention in medical literature, little information is available regarding which specific stimulants are used illicitly by college 
students" [41].
Examples of headlines "Student perceptions of methylphenidate abuse at a public liberal arts college" and "Stimulant medication use, misuse, and 
abuse in an undergraduate and graduate student sample".
Reported risks* Addiction (2); cardiovascular implications (1); withdrawal symptoms (1); increase in blood pressure (1); headache (1); 
overdose (1); blocking veins if injected/snorted (1); panic episodes (1); aggressive behavior (1); suicidal or homicidal 
tendencies (1).
Reported benefits† Decreases fatigue (2); increases energy (1); increases dopaminergic activity (1); maintain high performance level (1); increase 
alertness (1).
*Coded as physiological/psychological negative effects
†Coded as physiological/psychological positive effects
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medical uses for performance enhancement (20 PM; 14 B;
7 PH), which was a selection criteria, other uses of MPH
were generally discussed including medical uses to treat
AD/HD (16 PM; 5 B; 5 PH) and recreational uses (6 PM;
1 B; 7 PH).
In terms of risk and benefit statements, the risk of addic-
tion was present in all discourses while the print media
presented a wider variety of risks. However, in compari-
son to the prescribing information provided by Novartis
for MPH in the US, Canada, UK, and Australia [42-45]
(where the articles originated), most of these risks were
common risks and few of the uncommon and rare side
effects were featured.
Analyzed articles typically described: (1) who is using
MPH non-medically (e.g., college students; 18 PM; 8 B; 6
PH); (2) when MPH is used non-medically (e.g., during
final exams; 13 PM; 0 B; 3 PH); (3) where MPH is used
non-medically (e.g., college campuses and high schools;
11 PM; 5 B; 4 PH). Details were also reported, notably in
print media, on how students where securing MPH for
non-medical uses, i.e., by buying pills from other students
(14 PM; 1 B; 3 PH); by feigning symptoms of ADHD (5
PM; 0 B; 2 PH); through black markets (5 PM; 0 B; 1 PH);
through Internet pharmacies (4 PM; 0 B; 0 PH) and by
stealing pills (3 PM; 0 B; 1 PH).
The extent and social acceptance of non-medical uses of
MPH was described in divergent ways particularly in the
print media. We found contrasting statements that this
practice was: (1) "accepted" (6 PM; 0 B; 1 PH); (2) "fre-
quent" and "widespread" (16 PM; 8 B; 5 PH); (3) the sub-
ject of ambivalent opinions (6 PM; 0 B; 0 PH); (4)
"debatable" and "concerning" (10 PM; 1 B; 3 PH); and (5)
rare and anecdotal (6 PM; 0 B; 0 PH). Bioethics discourse
alluded to the treatment-enhancement dichotomy, often
judged to be blurry or misleading (2 PM; 9 B; 0 PH) to
understand the implications of non-medical use of MPH.
Ethical, legal and social issues of non-medical use of MPH
There were generally wide-ranging views on the ethical,
legal and social issues related to the non-medical use of
MPH. Table 4 provides an overview of the frequency and
distribution of ethical, legal and social issues within the
discourses examined. The issues most discussed across
discourses were social integration and acceptability (e.g.,
"Ritalin makes repetitive, boring tasks like cleaning your
room seem fun," (...) "I equate it in my mind with a really
Table 4: Frequency and distribution of ethical, social and legal issues associated with the non-medical use of methylphenidate (MPH) 
for performance enhancement in print media (PM), bioethics (B) and public health (PH) discourses.
Ethical, legal and social issues Affirmation Negation Total Frequency
PM B PH Total PM B PH Total
Social integration and acceptability 11 13 - 24 5 - - 5 29
Social meaning 11 9 5 25 1 2 - 3 28
Unsafe 2 11 2 15 3 2 2 7 22
Abuse 11 1 5 17 1 1 1 3 20
Cheating 5 8 - 13 3 3 - 6 19
Inauthenticity, identity and personhood 1 12 - 13 - 5 - 5 18
Injustice and inequalities - 10 - 10 - 6 - 6 16
Overprescription 9 2 4 15 1 - - 1 16
Lack of autonomy, individual choice and informed consent - 10 - 10 - 5 - 5 15
Illegality 8 2 - 10 3 1 - 4 14
Commercialization 1 7 - 8 - 1 - 1 9
Inefficacy 2 4 1 7 - - - - 7Page 5 of 13
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acts as a quick fix for problems that are the product of the
rapid-fire culture and the hurried society in which we live"
[17]), and safety (e.g., "Heiligenstein says that part of the
problem is a perception that prescription drugs, as
opposed to "street" drugs, are safe because they have been
officially approved" [37]).
Bioethics discourse was comprehensive in its coverage of
ethical and social issues generally representing both affir-
mations and negations, i.e., statements that an issue was
important and rebuttal statements of it. Some issues were
absent from print media and public health discourses:
inauthenticity, identity and personhood; lack of auton-
omy, individual choice and informed consent; injustice
and inequalities. Despite many negations that MPH is
unsafe, none of the discourses expressed the belief that we
had reliable evidence of efficacy to support such state-
ments. In fact, we only found seven negations i.e., there is
no reliable data on the cognitive enhancement effects of
MPH. All three discourses also seemed to converge, save
for one negation in the print media, on the topic that
MPH was overprescribed.
Generally, the ethical, legal and social issues related to the
non-medical use of MPH typically cautioned against more
widespread use. For example, issues like abuse; commer-
cialization; illegality; inauthenticity, identity and person-
hood; lack of autonomy, individual choice, and informed
consent as well as concerns regarding safety were more
often affirmed than negated. However, we observed
marked ambivalence with regard to other issues. For
example, on the topic of enhancement and cheating some
sources stated that the non-medical use of MPH creates an
unfair playing field (e.g., "Some students who don't use
the drug say their pill-popping classmates have an unfair
edge and consider use of the pills a form of cheating"
[47]) while others consider it as fair as private tutors (e.g.,
"You deserve to win a Nobel Prize if you discover the cure
for cancer, whether or not you do so with the aid of cog-
nitive enhancement drugs" [48]). We found a similar sit-
uation with respect to the issue of injustice and
inequalities. Some sources maintained that cognitive
enhancement cannot erase the "disparities created by nat-
ural talent and luck" [48] but others argued that "Unequal
access is generally not grounds for prohibiting neurocog-
nitive enhancement, any more than it is grounds for pro-
hibiting other types of enhancement, such as private
tutoring or cosmetic surgery that are enjoyed mainly by
the wealthy" [3].
Recommendations for the non-medical use of MPH
Many types of solutions were proposed to deal with non-
medical use of MPH [3,17,18,33,34,37,38,40,41,47-53]
Table 5: Proposed recommendations to prevent non-medical use of methylphenidate (MPH) and challenges associated with 
prevention.
A. Proposed recommendations to prevent non-medical use of MPH
Print media Bioethics Public health
Diagnosing ADHD more carefully [37,38,50]
Supervising of students with stimulant 
prescriptions [33,47]
Teaching students effective study skills and 
stress management [17,37]
Informing students and staff of the dangers of 
abusing prescription drugs [18,33,34,37]
Criminalizing non-approved uses of 
medications [3,48]
Prohibiting prescription of drugs for lifestyle 
purposes by doctors [48]
Obliging manufacturers to declare safety data 
for unapproved uses to the FDA [48]
Subsidizing cognition enhancing drugs to allow 
equal access [40,48]
Establishing a "ceiling" as the maximum 
cognitive enhancement permissible [48,53]
Ensuring prescription compliance and 
responsible prescription practices [49,52]
Prescribing preparations that are less easily 
abused [41,51]
Identifying persons who are liable to abuse 
medication [49]
Educating healthcare providers dealing with 
university populations as to the abuse potential 
of stimulants [51,52]
B. Identified challenges in the prevention of non-medical use of MPH
Print media Bioethics Public health
Logistical problems of enforcing a ban 
[37,38,54]
Perceived safety of MPH makes convincing 
students about its dangers more difficult 
[35,37]
Abundance of MPH in healthcare system [50]
Misuse of MPH bypasses traditional sources of 
information on indications and risks when 
taking a prescription medication [37]
Difficult to propose a ban on cognitive 
enhancers because of their routine use in 
treatment [40,48,53]
Ban is liable to encourage a black market and 
be just as coercive as social pressure [40,48,53]
FDA has little experience in assessing social 
cost/benefit of a drug and thus is unfit to take 
charge of such regulation [53]
None identifiedPage 6 of 13
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ures. These suggestions included restrictive legislation on
MPH and other potential performance enhancing drugs in
healthy people by criminalizing non-approved uses. Con-
trasting recommendations to facilitate access to these
drugs (e.g., government subsidies for those who cannot
afford the drugs) were also presented. The print media
and public health discourses promoted changing the hab-
its of healthcare professionals in diagnosis and prescrip-
tion and also informing students and university staff
about the misuse of prescription drugs and its risks.
Several challenges were highlighted regarding the preven-
tion of non-medical use of MPH
[35,37,38,40,48,50,53,54] (Table 5). These included the
logistical complexity and legitimacy of enforcing a ban
and the detrimental impact of a ban on patients who need
a drug to function. The most emphasized challenge was
the sense of security that individuals have with regard to
prescription drugs, because they are approved by govern-
mental health agencies.
Discussion
This study examined discourses on the non-medical use of
MPH by college students in the print media, bioethics lit-
erature, and public health literature. We found that there
were three distinct paradigms used to describe the non-
medical use of MPH. The "lifestyle choice" framework
expressed in the print media generally reflected the opin-
ion that the uses of neuropharmaceuticals for self-
improvement is a laudable goal and a personal choice.
The "prescription drug abuse" framework found in the
public health discourse views the non-medical use of neu-
ropharmaceuticals as illicit and a public health problem.
The "cognitive enhancement" framework in bioethics dis-
course focuses on the ethical issues arising from presumed
benefits of non-medical use of neuropharmaceuticals by
healthy individuals. These paradigms were reflected nota-
bly in the headline content across discourses and the state-
ments used to describe the non-medicinal use of MPH
itself (Table 3). The lifestyle paradigm is also well illus-
trated in the print media's use of lay designations (Table
2) and the enthusiastic terms used to describe its potential
beneficial enhancement effects of non-medical use of
MPH (Table 3). We observed diverging claims about the
frequency and acceptability of such MPH use. The print
media provided overall detailed descriptions of whom,
where, and when MPH was used non-medically and also
how students were procuring it. The ethical discussion
surrounding the non-medical use of MPH was without
surprise more comprehensive in the bioethics literature.
Overall, discussion of ethics was wide-ranging and only in
the public health literature was there a clear stand against
non-medical uses of MPH. Issues most frequently dis-
cussed concerned social aspects as well as safety consider-
ations of the non-medical use of MPH for performance
enhancement. Major areas of debate included whether
performance enhancement with MPH was considered
cheating as well as whether the phenomenon created
injustices and inequalities. Discourses converged on the
topics of overprescription of MPH and lack of reliable sci-
entific data for the enhancement effects of MPH. Recom-
mendations ranging from calls for legislation to increased
public education were identified in all three sources of
discourse but challenges to these recommendations were
only identified and discussed in the print media and in
the bioethics literature (Table 5).
Limitations
As with most qualitative research and discourse analyses,
some aspects of our study limit the generalization of the
results. First, the small sample size and limited sample
composition, in spite of broad searches and the use of
multiple databases, are not exhaustive of all discourses on
non-medical use of MPH. The results of this small study
should accordingly be viewed as a preliminary step to ful-
fill this larger goal. Second, the scope of the study was lim-
ited to a few countries, mostly because of the available
sources of the literature. Third, the specific case of the
non-medical use of MPH was examined even though
there are other drugs that are used in similar ways. How-
ever, this choice is supported by the draw of MPH for per-
formance enhancement as reported in a recent survey
published in Nature [48] and its well established use by
university students [6]. Fourth, the reported statements in
the print media articles are an amalgamation of opinions
from people interviewed by journalists and do not neces-
sarily reflect the opinions of journalists. Accordingly, the
print media content should be viewed as what was availa-
ble to the public through this channel rather than the
voice of journalists per se.
Disagreements between paradigms could have important 
healthcare, ethics, and social implications and 
consequences
The dissonance we observed between paradigms used to
describe and evaluate the non-medical use of MPH for
performance enhancement could have profound health-
care, ethics and social implications and consequences.
Each paradigm carries forward a distinct view of the
acceptability of MPH non-medical use. Speaking of a "life-
style choice", a "cognitive enhancement", or a "prescrip-
tion misuse" matters for scholarly biomedical ethics,
public debate, healthcare and public policy. A major
source of disagreement and concern is the unbalanced
presentation of the potential positive and negative effects
of MPH across discourses. In the print media especially, a
fair number of potential adverse effects (Table 3) are men-
tioned but most often without qualification or quantifica-
tion. In contrast to the risks, the positive effects arePage 7 of 13
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"smart drug" (Table 2). As suggested by Rajczi [55], such
enthusiastic discourses about new technologies can arise
from society's assumption that they are intrinsically valu-
able but can be independent of the scientific evidence.
Furthermore, Lanni et al. argue that: "From a pharmacol-
ogy point of view the fact that a drug is clinically used to
treat an attention disorder or a cognitive problem does
not necessarily mean that a high level of the relevant mol-
ecule would produce a high performance in a normal
individual" [56]. To date, the benefits of cognitive
enhancement for healthy individuals appear to be based
on media reports and a few scientific studies. However,
the alleged efficacy of cognitive enhancers is an important
area of disagreement and diverging perspectives.
Before rallying behind cognitive enhancement and most
definitely before any kind of regulation or approval is put
forward, current scientific data must be assessed and inter-
preted carefully beyond general assumptions inherent in
terms like "cognitive enhancers" and "smart drugs". Con-
trary to some implicit assumptions found in bioethics and
media discourses, there are actually only a few studies on
the enhancement effects of cognitive enhancers on
healthy individuals. The findings of these studies may in
fact be limited in their potential to be generalized and
support favorable opinions toward the cognitive enhance-
ment of healthy individuals. For example, Elliott et al.'s
often-cited, double-blind, placebo-controlled study
showed that methylphenidate positively impacted per-
formance on spatial working memory and planning but
not on attention and fluency tasks. However, the results
also showed that methylphenidate did not enhance per-
formance tasks that were already learned [57]. The study
conducted by Mehta et al. investigated changes in regional
cerebral blood flow as an indication that methylpheni-
date enhances spatial working memory [58]. Barch et al.
obtained results similar to the findings of Elliott et al. and
Mehta et al. that amphetamine enhanced spatial working
memory [59]. In contrast to the three previous studies,
Bray et al. reported that methylphenidate does not
enhance the cognition of sleep-deprived individuals [60].
Farah et al. recently examined the effect of Adderall upon
creativity, a component of cognition stimulants are sus-
pected of stifling, in a double-blind, placebo-controlled
trial [61]. They found that the drug indeed enhanced cre-
ativity on specific tasks but the amount of enhancement
depended upon the baseline performance of individuals:
lower-performing individuals were more enhanced than
high-performers. The conflicting and fragmented results
of these few studies currently provide limited support for
the enthusiastic portrayals of cognitive enhancement.
To date, the studies supporting enthusiastic media and
bioethics discourses do not reflect the reality of research
on MPH-based enhancement. Several aspects of early
research need to be further examined and reproduced.
First, generalizing results at this point is imprudent given
the small and homogeneous cohorts involved. Samples in
these studies range from ten to twenty-eight participants
and most of them are young healthy males. Current
parameters cannot account for variable efficacy in individ-
uals which would result in certain types of individuals
being unable to enhance themselves thus perpetuating the
debates on justice because of unequal effects. Second, the
specific experimental nature of the tasks used for research
does not necessarily reflect real-world performance in
complex contexts. Further, Farah et al.'s results show that
there may be an "enhancement ceiling" for certain types
of individuals or tasks. Third, there is limited understand-
ing of the long-term effects of MPH and other drugs used
for enhancement. Presently, for treatment with MPH last-
ing more than four weeks, it is strongly recommended
that the treating physician regularly reevaluate the neces-
sity for the prescription for MPH [62]. The survey on cog-
nitive enhancement conducted by Nature revealed that
respondents used cognitive enhancers on daily, weekly
and monthly bases in almost even proportions [63] which
indicated that enhancement may become a habit. In the
laboratory setting, MPH has been shown to have an abuse
potential under certain conditions [11-14] that may result
in addiction with regular use of cognitive enhancers. In
contrast to enthusiastic media and bioethics discourses,
these observations have the potential to show that non-
medical use of MPH may be less valuable than some
expect because of the scientific and medical limitations of
the drug effects.
The reported positive effects in the print media are largely
based on anecdotes and are typically not adequately con-
trasted with scientific data about the effects of MPH on the
healthy brain. Given these features, some enthusiastic
interpretations found in print media as well as bioethics
discourse could contribute to the unintended dissemina-
tion of a poorly understood non-medical use of MPH for
performance enhancement. However, if public health dis-
courses prematurely condemn this practice as a form of
drug abuse, future public health strategies risk being ill-
equipped to tackle the enthusiasm and interest for cogni-
tive enhancers found in other discourses and perhaps in
the public.
Bioethics and the print media need to sustain public 
information and socially-informed public debate
Bioethics discourse and, to some extent, the print media,
contained extensive discussions on the ethics of the non-
medical use of MPH. Nonetheless, our results suggest that
the coverage of the phenomenon in these discourses
brings about sources of confusion. For instance, there is a
wide range of uncertain claims about the prevalence andPage 8 of 13
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veys in many respects more sociological details and con-
text (e.g., who, how, when and where) regarding the non-
medical use of MPH for performance enhancement. How-
ever, this may have unexpected consequences such as
increasing the prevalence of the practice. In fact, the com-
bination of consumption details and student testimonials
with positive portrayals of the performance enhancement
potential of MPH in the print media may incite individu-
als to engage in the practice.
Our results also suggest that using MPH for enhancement
is already considered an integral part of social practice in
some discourses. They show that some media reports con-
sider MPH comparable to "traditional" methods of
enhancement that are acceptable such as consuming caf-
feine. Combined with praise of MPH as a "miracle drug",
this perceived social integration can build additional fer-
vor for cognitive enhancement. This perception may be a
reflection of the social context in which cognitive
enhancement is emerging and would need to be captured
in the bioethics discussion. Recent work on the medicali-
zation of sleep and non-medical uses of modafinil has
linked the acceptability of pharmacological enhance-
ments to the context of use [64]. In his book Listening to
Prozac, Kramer postulates that: "The operational defini-
tion of wellness must be in relation to the demands and
goals of society, here and now" [65]. Not only does social
context first modulate the definition of health on the
treatment-enhancement spectrum but it also affects other
issues. For example, coercion of individuals to use cogni-
tive enhancers is often cited as an issue in the literature
[3,40,48]. It was also identified as an important issue in
our present discourse analysis. However, the specific
nature of coercion remains vague without an indication of
what causes this coercion and what stakeholders stand to
gain. Both of these aspects are partly shaped by social con-
text and are important to consider in ethical discussion
and policy. However, critical outlooks on social context
could pose a real challenge given the favorable opinions
of influential bioethicists who emphasize the role of per-
sonal choice and individual rights in the choice to
enhance cognition [66]. Even though we found some
aspects of media and bioethics discourses to be favorable
and enthusiastic, they can also serve as important venues
to voice attitudes and informing the public of the risks
associated with neuropharmaceuticals.
The nature of information disseminated to the public is
also of the utmost importance. There are potentially some
valuable lessons about reporting on non-medical uses of
MPH and other pharmaceuticals that can be gleaned from
the guidelines put forth by the Australian Press Council.
The Council's guidelines relate to journalistic reporting on
illicit drug use (drug addiction). They recommend avoid-
ance of reporting "stories that might excite the interest of
young people in drug experimentation, including the
naming of dangerous drugs". The recommendations for
reporting on addictive drugs also state that "the harmful
effects of any particular drug should not be exaggerated or
minimized"; and that we should "avoid detailed accounts
of consumption methods, even though many young peo-
ple are generally familiar with them." The recommenda-
tions also "guard against any reporting which might
encourage readers' experimentation with a drug, for exam-
ple highlighting the 'glamour' of the dangers involved"
[67]. Though using neuropharmaceuticals to enhance
cognitive performance happens in a different context than
illicit drug abuse they do share some similarities. The
thinking behind these guidelines could translate into
avoidance of narratives and salient practices related to
non-medical MPH by students as well as other forms of
non-medical use of prescription drugs. This represents a
strong stance that could appear paternalistic and an inter-
ference with good reporting practices but the onus of
responsible reporting does not lie exclusively upon jour-
nalists. There are various stakeholders that could posi-
tively contribute to the ethical deliberation on cognitive
enhancement and several reasons why their input would
be beneficial. For instance, healthcare providers being
interviewed on this topic may want to be vigilant about
the opinions they express to journalists about non-medi-
cal practices especially regarding risks and benefits. For
example, we found a clinical psychiatrist that was quoted
as saying "Caffeine is fine. This is better (...) Students are
able to accumulate more information in a shorter time
frame. These drugs keep you awake longer. They minimize
fatigue and help maintain a high performance level" [47].
Perhaps healthcare professionals should be careful with
such public comments on non-medical uses of pharma-
ceuticals. Public health agencies must also be aware of
enthusiastic media reports if they want to counterbalance
unwarranted messages in the media and better inform the
public and stakeholders. These are some initial venues to
explore to improve the commitment to public informa-
tion and informed debate on non-medical uses of pre-
scription drugs for enhancement purposes.
Beyond the improvement of journalistic practices and the
responsible involvement of healthcare providers in stories
about the non-medical use of MPH, broader public
engagement needs further consideration given the stakes.
Though the decision to use a neuropharmaceutical for
cognitive enhancement may be up to the individual, the
effects of the enhancement loom much larger. The choices
of individuals may impact collective behaviors which
clearly makes the subject of cognitive enhancement a pub-
lic matter. However, public engagement is more than just
informing the public. It is also listening to public voices.
Racine et al. have proposed a model where inquiry andPage 9 of 13
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multi-dimensional communication between the scientific
community, humanities and social science, the media as
well as the public and stakeholders [30]. With this model,
knowledge about advances in neuroscience (or other
branches of science) does not end when it reaches the
public. Instead, public perceptions and opinion are fed
back up the chain of knowledge to instruct the scientific
community about what the public has understood about
its work. Possibly the most interesting aspect of this
model is that there is also dialogue between other stake-
holders. The multi-directional aspect of models like these
pave the way to engaging stakeholders in ethical discus-
sion of cognitive enhancement to provide a richer and
broader spectrum of perspectives.
Medicine, healthcare, and society need to prepare for 
broader and more prevalent non medical uses of 
pharmaceuticals
In our study, public health discourses on enhancement
raised many concerns about the non-medical use of MPH
for performance improvement because of its potential
health consequences. The prevalence of this practice with
MPH, which ranges from 3.2% to 11%, [51,52] is worri-
some from a healthcare perspective since it involves the
use of a controlled substance by individuals outside of the
intended clinical context. This trend has the potential to
pave the way for the general acceptability of non-medical
uses of other pharmaceuticals. Accordingly, societies
could be faced with serious public health challenges
before the ethics of this practice is properly discerned and
publicly debated. The 2007 report on enhancement from
the British Medical Association discussed whether a role
for public health was timely but did not conclude on the
subject [1]. We did note that wide ranging solutions were
suggested to prevent the expansion of the non-medical
use of MPH for enhancement purposes (Table 5). Devel-
opment of legislation on non-medical uses and distribu-
tion of prescription medications as well as the education
of healthcare professionals and the public about the dan-
gers of misusing prescriptions were common suggestions.
It should be noted that possession of a prescription drug
without permission and trafficking can have criminal
implications but this has not discouraged non-medical
uses for performance enhancement. Furthermore, stu-
dents who feign symptoms of AD/HD can acquire legiti-
mate prescriptions for non-medical motives.
This situation mirrors to some extent the widespread ille-
gal provision of human growth hormone (hGh) in the US
[68]. The recent recommendations in Olshanky and Pers'
paper regarding this practice focus mostly on the illegal
distribution of hGh by manufacturers but also high-
lighted the ethical responsibilities of healthcare profes-
sionals. Though the stakeholders in cognitive
enhancement with neuropharmaceuticals are different
than in hGh, there appear to be similar problems with
fraudulent sales online and trafficking of MPH among stu-
dents [37,63]. Prevention of these types of distribution,
stricter prescription practices, better patient prescription
compliance and effective, balanced information to the
public could help decrease prevalence and social integra-
tion of the practice in the absence of medical, social, and
ethical consensus about its acceptability. Regulatory bod-
ies and policy makers could begin examining the hGh rec-
ommendations as well as their associated challenges to
model potential action with regard to the emerging prac-
tice of the non-medical use of MPH. However, before any
new policies are made there clearly needs to be a broader
debate on the non-medical uses of neuropharmaceuticals
in order to sort through ethical and social issues.
At this time many consider that the non-medical use of
MPH for cognitive enhancement happens outside the
confines of medicine. Physicians and allied healthcare
professionals could be eased out of their role as "gatekeep-
ers" to these types of drugs as suggested by Chatterjee [69].
Unfortunately, it is not well-known if all healthcare pro-
viders are aware of the prevalence of the non-medical use
of methylphenidate and other neuropharmaceuticals for
enhancement or if they would feel concerned at all. Data
from the US National Institutes of Health shows that over
40% of healthcare providers have difficulty addressing the
subject of prescription abuse with their patients. For phy-
sicians, the subject of prescription abuse appears to be
even more difficult to tackle than stigmatized conditions
like depression and alcoholism [70]. A survey of general
practitioners on the subject of enhancement with pharma-
ceuticals in the Scandinavian Journal of Public Health indi-
cated that general practitioners were not open to the use
of prescriptions for enhancement purposes [71]. These
results suggest that healthcare providers are not fully
aware of the prevalence of the non-medical use of phar-
maceuticals for enhancement and that they potentially
perceive enhancement to be outside the boundaries of
medicine and perhaps out of their professional role. Even
though some areas of medicine may consider cognitive
enhancement to be outside of the realm of healthcare,
some aspects of the phenomenon may call for public
health interventions. This creates a vexing situation where
healthcare providers' view of cognitive enhancement as a
non-medical practice could curtail consideration of its
public health implications. However, even when the pills
are obtained on the black market they still, most likely,
were paid for by some patient's health insurance. Conse-
quently, the use of medical personnel and financial
resources for cognitive enhancement of healthy individu-
als could be putting a strain on healthcare systems.
Viewed in this light, users of cognitive enhancers mayPage 10 of 13
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consuming medical resources.
Currently, public health action for the prevention of the
non-medical use of pharmaceuticals for cognitive
enhancement faces some important challenges. First, it is
important that healthcare professionals become more
aware of the non-medical use of pharmaceuticals for cog-
nitive enhancement. This would likely make them more
comfortable discussing the topic. Second, the burden of
responsible management of prescriptions may well fall on
healthcare professionals and patients alike but the reality
is that healthcare providers have little or no control over
what is done with prescriptions when patients leave their
offices. Public health information campaigns trying to
prevent prescription misuse could perhaps more directly
target enhancement uses of prescriptions. Lastly, in raising
awareness among the public with regard to cognitive
enhancement public health faces a possible conflict of val-
ues. On one hand, public health action aims to prevent
practices that are potentially harmful to the public's
health like taking a pharmaceutical without a prescrip-
tion. On the other hand, raising awareness may inadvert-
ently promote forms of cognitive enhancement of healthy
individuals. Public health interventions will need to care-
fully consider how to play a role in cognitive enhance-
ment.
Conclusion
This study examined diverging discourses on the non-
medical use of methylphenidate for performance
enhancement. Our research yielded thought provoking
results on the respective portrayals of such use of MPH in
print media, bioethics and public health discourses. We
have highlighted some of the potential implications of
current discourses, notably the enthusiastic portrayals of
the non-medical use of MPH in the print media and
bioethics discourses despite scarce scientific data support-
ing its enhancement effects. In light of the diverging views
on ethics and enhancement but the increasing salience of
debates on "cognitive enhancers", we believe that public
action and more accurate representation of current scien-
tific evidence are needed. Engagement of stakeholders and
the general public could enrich the discussion and pro-
vide broader perspectives on the non-medical use of
MPH.
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